Want to see HCAT full AI Analyst Report?
HCAT Stock Chart & Stats
$2.08
$0.07(3.48%)
At close: 4:00 PM EDT
$2.08
$0.07(3.48%)
Day’s Range― - ―
52-Week Range$0.96 - $3.88
Previous Close$2.08
Volume423.78K
Average Volume (3M)628.93K
Market Cap
$154.44M
Enterprise Value$153.95
Total Cash (Recent Filing)$108.82M
Total Debt (Recent Filing)$170.58M
Price to Earnings (P/E)―
Beta1.54
Next Earnings
Nov 10, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.72
Shares Outstanding73,894,020
10 Day Avg. Volume592,331
30 Day Avg. Volume628,929
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.68
Price to Sales (P/S)0.54
P/FCF Ratio-704.86
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$2.29Price Target Upside9.89% Upside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)0.06
Revenue Forecast (FY)$263.79M
Bulls Say, Bears Say
Bulls Say
Balance-sheet De-riskingThe Vitalware divestiture and full prepayment of the term loan materially lowers leverage and interest burden, improving financial flexibility. This durable reduction in fixed financing costs strengthens the company’s ability to fund product investment and absorb migration headwinds over the next 2–6 months and beyond.
Positive Cash GenerationReturn to positive operating and free cash flow signals that core operations can generate liquidity despite GAAP losses. Sustained cash generation supports restructuring (Project NEXUS) and product development without immediate capital raises, making near-term strategic moves more durable if consistency is maintained.
Higher-margin Tech & AI MomentumA strategic shift to technology and AI-enabled offerings increases recurring, scalable revenue and drives higher gross margins over time. Proprietary improvement data and early positive customer feedback on Ignite Intelligence support differentiation and margin expansion potential, underpinning sustainable operating leverage.
Bears Say
Migration-driven Churn / At-risk ARRSignificant at-risk ARR from DAS→Ignite migrations creates a structural headwind to recurring revenue and visibility. If retention does not improve, churn could offset bookings and cost savings, prolonging the recovery timeline and pressuring revenue durability over the next 12–24 months.
Persistent GAAP LossesDeep and widening GAAP losses erode equity value and limit reinvestment capacity. Even with de‑leveraging and positive cash flow, sustained profitability is needed to restore return metrics; failure to convert margin improvements into GAAP profits risks recurrent dilution or constrained strategic options.
Services Margin Decline & Transitional Cost PressureThe deliberate services-to-technology shift reduces lower-margin services revenue but also removes a revenue cushion while services margins compress. Transitional duplicate hosting/data-load costs further depress short-term gross margins, raising execution risk that cost saves and margin targets may lag revenue declines.
Health Catalyst News
HCAT FAQ
What was Health Catalyst’s price range in the past 12 months?
Health Catalyst lowest stock price was $0.95 and its highest was $3.88 in the past 12 months.
What is Health Catalyst’s market cap?
Health Catalyst’s market cap is $154.44M.
When is Health Catalyst’s upcoming earnings report date?
Health Catalyst’s upcoming earnings report date is Nov 10, 2026 which is in 95 days.
How were Health Catalyst’s earnings last quarter?
Health Catalyst released its earnings results on Aug 06, 2026. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.01.
Is Health Catalyst overvalued?
According to Wall Street analysts Health Catalyst’s price is currently Undervalued.
Does Health Catalyst pay dividends?
Health Catalyst does not currently pay dividends.
What is Health Catalyst’s EPS estimate?
Health Catalyst’s EPS estimate is <0.01.
How many shares outstanding does Health Catalyst have?
Health Catalyst has 73,894,020 shares outstanding.
What happened to Health Catalyst’s price movement after its last earnings report?
Health Catalyst reported an EPS of $0.04 in its last earnings report, beating expectations of $0.03. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Health Catalyst?
Currently, no hedge funds are holding shares in HCAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Health Catalyst Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.29 (9.89% Upside)
$2.29 (9.89% Upside)
Blogger Sentiment
Neutral
HCAT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 793.7K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-53.77%
Trailing 12-Months
Company Description
Health Catalyst
Health Catalyst, Inc. equips healthcare providers with crucial data and analytical technologies, alongside specialized services. Their extensive product line features a robust, enterprise-level data and analytics platform designed specifically for the healthcare sector. They additionally offer advanced artificial intelligence (AI) and data science solutions that integrate AI seamlessly into existing business intelligence tools, thereby enhancing analytical precision. The company's services also cover population health management, which identifies areas for improvement throughout the patient care journey, offering actionable recommendations and automated processes. For financial effectiveness, they provide critical insights into cost analysis, workforce efficiency, and revenue maximization. Moreover, Health Catalyst contributes to improving quality and safety by leveraging clinical and patient safety data, sophisticated analytics, and expert consulting. They also facilitate a national data ecosystem, promoting collaborative thought leadership and shared knowledge to generate groundbreaking insights that redefine healthcare delivery. Established in 2008 and based in South Jordan, Utah, the company was formerly known as HQC Holdings, Inc. before officially becoming Health Catalyst, Inc. in March 2017.
HCAT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced clear operational and financial progress with meaningful near-term headwinds. Positives include a revenue beat, improved adjusted gross margin, a sizable adjusted EBITDA beat, strong cash generation, a detailed restructuring program (Project NEXUS) targeting ~$30M of annualized savings, early product and AI traction, and reinstated full-year guidance. Negatives center on migration-driven churn (~$30M at-risk ARR with an expected ~$20M 2026 impact), transitional duplicate hosting and data-loading costs weighing on margins, expected professional services margin decline, and near-term restructuring charges and execution risk. Overall, management laid out a coherent plan to address issues and improve long-term durability but acknowledged short-term revenue and margin pressure tied to migration and transformation.View all HCAT earnings summariesHCAT Stock 12 Month Forecast
Average Price Target
$2.29
▲(9.89% Upside)
Technical Analysis
Evolent Health
―
Phreesia
―
Privia Health Group
―
Definitive Healthcare Corp
―
Waystar Holding Corp.
―
Ownership Overview
7.88% Insiders
13.29% Mutual Funds
0.82% Other Institutional Investors
71.84% Public Companies and
Individual Investors